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Influenza illness is caused by influenza A and influenza B strains. 
Although influenza A viruses are perceived to carry greater risk 
because they account for the majority of influenza cases in most 
seasons and have been responsible for influenza pandemics, influ-
enza  B viruses also impose a substantial public health burden, 
particularly among children and at-risk subjects.
Furthermore, since the 2001-2002 influenza season, both influ-
enza  B lineages, B/Victoria-like viruses and B/Yamagata-like 
viruses have co-circulated in Europe.
The conventional trivalent influenza vaccines have shown a lim-
ited ability to induce effective protection when major or minor 
mismatches between the influenza B vaccine component and cir-
culating strains occur. For this reason, the inclusion of a second B 
strain in influenza vaccines may help to overcome the well-known 
difficulties of predicting the circulating B  lineage and choosing 
the influenza B vaccine component.
Two quadrivalent influenza vaccines, a live-attenuated quad-
rivalent influenza vaccine (Q/LAIV) and a split inactivated 
quadrivalent influenza vaccine (I/QIV), were first licensed 
in the US in 2012. Since their introduction, models simulat-
ing the inclusion of QIV in influenza immunization programs 
have demonstrated the substantial health benefits, in terms of 
reducing the number of influenza cases, their complications 
and mortality.
In the near future, evaluations from simulation models should 
be confirmed by effectiveness studies in the field, and more cost-
effectiveness analyses should be conducted in order to verify the 
expected benefits.
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Summary
Introduction
Influenza is an acute viral illness of the respiratory 
tract, and constitutes a substantial public health bur-
den in terms of morbidity, mortality and related costs. 
About 3-5 million cases of severe illness occur each year 
worldwide, resulting in about 250,000 to 500,000 deaths 
per year, high hospitalization and mortality rates, and 
considerable loss of productivity [1-3].
From a microbiologic point of view, type A and type 
B Influenza viruses differ markedly in terms of their 
hosts and epidemiology. Influenza  A viruses have 
other animal reservoirs, in addition to humans, and 
display high antigenic variability, which mainly in-
volves their surface glycoproteins: hemagglutinin 
(HA) and neuroaminidase (NA). Antigenic shift and 
antigenic drift are the two well-known mechanisms 
responsible for major and minor variations; antigenic 
shift is the main cause of the appearance of new in-
fluenza A strains with pandemic potential. Antigenic 
drift determines annual seasonal influenza epidem-
ics [4].
Influenza  B viruses, for which humans are the sole 
host of epidemiological relevance, do not undergo 
antigenic shift, but they can undergo antigenic drift. 
Since at least 1983, two parallel evolutionary B path-
ways with little antigenic cross-reactivity have been 
recognized, thus allowing two distinct genetic lin-
eages to be identified: the B/Victoria/2/1987 (Victo-
ria) and B/Yamagata/16/1988 (Yamagata) strains  [5-
6]. Since 2002, the two distinct influenza B lineages 
have frequently co-circulated, with one of the two 
predominating over the other in each season [7]. For 
example, in ten consecutive influenza seasons in Ita-
ly – from 2003-2004 to 2012-2013 – variations in the 
prevalence of circulating B  lineages were reported: 
in 2007/2008 and 2012/2013, B viruses accounted 
for 47.7% and 58%, respectively, of viruses isolated, 
while in other seasons  B viruses co-circulated with 
virus A, although with a lower prevalence [8].
Vaccination is the most effective means of reducing 
the number of influenza cases and related complica-
tions. Annual influenza immunization is, in particu-
lar, recommended in elderly subjects, children aged 
six months or more, pregnant women and individu-
als with chronic conditions, such as respiratory/heart/
liver diseases, diabetes, or a weakened immune sys-
tem. Indeed, these categories are at heightened risk 
of influenza-related complications and mortality [9].
In Italy, the National Ministry of Health annually pub-
lishes influenza prevention recommendations, speci-
fying the groups to whom vaccination is offered free 
of charge. In addition, the Ministry sets a minimum 
target of vaccination coverage of 75% and an optimal 
target of 95% [10].
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The World Health Organization (WHO) annually rec-
ommends vaccine composition on the basis of global 
virological surveillance. Annual trivalent influenza vac-
cines (TIVs) contain two influenza A strains (H1N1 and 
H3N2) and only one influenza B virus. The effectiveness 
of TIVs therefore depends on the degree of matching be-
tween the vaccine strain and circulating viral strains.
In the last two decades, four major and at least eight mi-
nor mismatches between vaccine and circulating B vi-
ruses have occurred in the northern hemisphere, thus 
impairing the performances of TIVs (Tab.  I)  [6]. Spe-
cifically, Ambrose CS and colleagues observed that, in 
Europe, a B-mismatch between vaccine and circulating 
strains occurred in 5 of 10  seasons between 2001 and 
2011 [7]. The effect of antigenic mismatching between 
vaccine and circulating strains on vaccine effective-
ness has emerged from observational and experimental 
studies  [6, 11-14]. A recent meta-analysis by the Cen-
ters for Disease Control and Prevention (CDC) and the 
Marshfield Foundation reported that trivalent subunit or 
split influenza vaccines displayed good effectiveness in 
preventing lab-confirmed influenza illness when match-
ing was good, but that vaccine effectiveness decreased 
when a drifted strain dominated the epidemiological 
picture [15]. Therefore, inaccurate prediction of the pre-
dominant influenza  B lineage leaves many vaccinated 
individuals with suboptimal protection against influ-
enza  B disease caused by the influenza B lineage not 
included in the licensed trivalent vaccine [11].
To minimize the impact of B-mismatch on vaccine 
effectiveness, in February  2009 the Food and Drug 
Administration (FDA), for the first time, considered 
the inclusion of an additional influenza  B strain in 
the antigenic composition of seasonal influenza vac-
cines [16]. Subsequently, in February 2012, the WHO 
recommended the production of quadrivalent influ-
enza vaccines (QIVs) for seasonal immunization. 
In 2012, the European Medicines Agency (EMA) also 
highlighted the need for a quadrivalent vaccine that 
could overcome the lack of protection against the in-
fluenza B lineage not present in the trivalent vaccine. 
Finally, in February  2013, the WHO issued its first 
guidelines recommending that both expected B-strains 
be included in the vaccine composition [17-18].
In recent years, scientific research has addressed this 
need, and two quadrivalent influenza vaccines (QIVs) 
have been developed: a live-attenuated quadrivalent in-
fluenza vaccine (Q/LAIV) and a split inactivated quadri-
valent influenza vaccine (I/QIV) [19].
Main evidence from pre- and post-
marketing evaluations of licensed 
quadrivalent influenza vaccines
The immunogenicity, safety and tolerability of quadriva-
lent influenza vaccines have been evaluated in children, 
adults and the elderly in several clinical trials.
Tab. I. Influenza vaccination strains and viruses circulating in the northern hemisphere in the seasons from 1995/96 to 2015/2016.
Season Influenza vaccination strains, Northern Hemisphere Virus circulating in Europe and US
A/H1N1 A/H3N2 B A/H1N1 A/H3N2 B
1995/96 Texas/91 Johan/94 Beijing/93 Texas/91 Johan/94 Beijing/93
1996/97 Bayern/95 Wuhan/95 Beijing/93 Bayern/95 Wuhan/95 Beijing/93
1997/98 Bayern/95 Wuhan/95 Beijing/93 Bayern/95 Syd/97 Harbin/94
1998/99 Beijing/95 Syd/97 Beijing/93 Bay/95+Beij/95 Syd/97 Beijing/93
1999/00 Beijing/95 Syd/97 Beijing/93 NewCal/99 Syd/97 Beijing/93
2000/01 NewCal/99 Pan/99 Yaman/98 Bay/95+NC/99 Syd/97 Sichuan/99
2001/02 NewCal/99 Pan/99 Sich/99 (Y) NewCal/99 Pan/99 Sic/99+HK01
2002/03 NewCal/99 Pan/99 HK/01 (V) NewCal/99 Fuj/02(Pan/99) Sic/99+HK01
2003/04 NewCal/99 Pan/99 HK/01 (V) NewCal/99 Fuj/02 Jiangs/03
2004/05 NewCal/99 Wyom/03 Jiangs/03 (Y) NewCal/99 Calif/04 J/03+Mal/04
2005/06 NewCal/99 Calif/04 Jiangs/03 (Y) NewCal/99 Cal/04+Wis/05 J/03+Mal/04
2006/07 NewCal/99 Wiscons/05 Malays/04 (V) NC/99+Sal/06 Wisc/05 J/03+Mal/04
2007/08 Salom Is/06 Wiscons/05 Malays/04 (V) Sal/06+Bris/07 Wisc/05+Bris/07 Bri/07+Mal/04
2008/09 Bris/07 Bris/07 Florida/06 (Y) Bris/07 Bris/07 Florida/06+Brisb/08
2009/10 Bris/07 Bris/07 Bris/08 (V) - Bris/07 Bris/08 (V)
2009/10 Calif/09 Calif/09
2010/11 Calif/09 Perth/09 Bris/08 (V) Calif/09 Perth/09 Bris/08 (V)
2011/12 Calif/09 Perth/09 Bris/08 (V) Calif/09 Vict/11+Brisb/11 Bris/08+Wisc/10
2012/13 Calif/09 Vict/11 Wiscons/10 (Y) Calif/09 Vict/11+Texas/12 Bris/08 (V)+Mass/12 (Y)
2013/14 Calif/09 Vict/11 Mass/12 (Y) Calif/09 Texas/12 Bris/08 (V)+Mass/12 (Y)
2014/15 Calif/09 Texas/12 Mass/12 (Y) Calif/09 Switzerl/13 +Texas/12 Phuk/13(Y)+Mass/12(Y)
2015/16 Calif/09 Switzerl/13 Phuk/13(Y) Calif/09 Hong Kong/14 Bris/08 (V)+Phuk/13 (Y)
Legend: in yellow: minor mismatches; in red: major mismatches; in green: new influenza A strains with pandemic potential.
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Live-attenuated quadrivalent influenza 
vaccine (Q/LAIV)
Q/LAIV has mainly been tested in children. A phase-
III, randomized, double-blind study performed on 2,312 
children aged 2-17 years demonstrated that the immu-
nogenicity of an investigational Q/LAIV was non-infe-
rior to that of two licensed T/LAIVs, one containing a 
B strain from the Yamagata lineage and the other con-
taining a strain from the Victoria lineage. Moreover, this 
Q/LAIV proved safe and well tolerated [20].
Since 2014/2015, Q/LAIV has been used in a universal 
pediatric vaccination programme in the United Kingdom 
(UK). In this real-life scenario, the vaccine was seen to 
provide significant protection against drifted circulating 
influenza B viruses [21].
Inactivated quadrivalent influenza vaccine 
(I/QIV)
Children and adolescents
With respect to I/QIV, a phase II study was conducted 
in two groups of children aged 18-47 months: the first 
group was constituted by children who had received 
two doses of TIV in the previous season and who re-
ceived one dose of TIV or I/QIV in the study season; 
the second group was composed of unprimed children 
who received two doses of I/QIV or TIV 28 days apart 
during the study season. In comparison with the TIV, 
the I/QIV displayed superior immunogenicity towards 
the alternative-lineage B  strain, without impairing the 
immune responses to shared strains. Moreover, the two 
vaccines proved similar in terms of reactogenicity and 
safety [22]. These results were confirmed in a random-
ized phase  III study conducted by Domachowske JB 
and colleagues in healthy children aged 3-17 years [23]. 
Langley and colleagues also investigated the immuno-
genicity and safety of a I/QIV candidate versus TIVs, in 
a phase-III randomized controlled trial involving 3,094 
children aged 3-17 years. The I/QIV was non-inferior to 
the TIVs in terms of immunogenicity towards the shared 
strains (A/H3N2 and A/H1N1), and, in comparison with 
TIV controls, elicited superior responses to the added 
B strains. Solicited reactions, unsolicited adverse events 
and serious adverse events were similar in the I/QIV and 
pooled TIV groups [24].
Adults and elderly 
The promising results obtaining with I/QIV in children 
were also confirmed in clinical trials performed in adult 
populations.
In a phase-III clinical trial comparing I/QIV with TIV/
Victoria and TIV/Yamagata vaccines, 4,659 adult volun-
teers received one vaccine dose. Overall, the I/QIV was 
highly immunogenic and, on day 21, displayed greater 
immunogenicity towards the additional B strain than 
TIV, without interfering with the antibody responses to 
the three shared antigens [25]. The I/QIV candidate was 
also tested in 1,565 adults aged ≥ 18 years in a phase III, 
randomized, active-controlled, multicenter trial during 
the 2011/2012 influenza season. For all four vaccine 
strains, antibody responses to the I/QIV were non-in-
ferior to those elicited by the TIV for matched strains. 
For both B strains, antibody responses to the I/QIV were 
non-inferior to the response to the TIV for the matched 
strains, and were superior to the responses elicited by the 
TIVs that lacked the corresponding B strain. The I/QIV 
also confirmed its acceptable safety profile in an adult 
population [26].
The safety of I/QIV was investigated through a routine 
surveillance system in Western Australia in 2015 in a 
sample of 1,685 healthcare workers (HCWs). The re-
sults indicated little difference between the reactogenic-
ity of I/QIV and that of TIV; the percentage of HCWs re-
porting pain or swelling at the injection site was slightly 
higher among those who had received I/QIV than those 
who had received TIV (6.9% vs 4.2%, respectively; 
p = 0.02) [27].
The safety of I/QIVs was verified in a review of data 
from the Vaccine Adverse Event Reporting System 
(VAERS) in the US from 7/1/2013 to 5/31/2015. The 
most frequent non-fatal serious adverse events were: in-
jection site reactions, such as pain and erythema, consti-
tutional symptoms, Guillain-Barré syndrome, seizures, 
and anaphylaxis, though these were rare or very rare. 
Adverse events reported to the VAERS following I/QIVs 
were similar to those following TIVs [28].
On the basis of this evidence, the two quadrivalent in-
fluenza vaccines have recently been licensed in many 
countries, and have been gradually replacing TIVs in the 
immunization programs of these countries.
Expected benefits of the quadrivalent 
influenza vaccines 
As mentioned above, two different influenza B strains 
may co-circulate during an influenza season. Therefore, 
adding a second B strain to influenza vaccines increases 
the likelihood of achieving adequate protection against 
influenza B disease. Some recent studies have evaluated 
the expected benefits of including QIVs in national im-
munization programs. For instance, Eichner et al. com-
pared the effects of QIVs and TIVs on influenza inci-
dence by using an individual simulation model in which 
the concomitant transmission of four influenza strains, 
maternal protection, boosting of existing immunity, loss 
of immunity and cross-immunizing events between the 
B lineages over 50 years were considered as variables. 
Their study found that QIV administration could pre-
vent 11.2% of all influenza B infections which still oc-
cur with TIV, thus reducing the influenza burden on the 
community [29]. 
The public health impact of QIVs in the United States 
was analyzed in a model by Crépey and colleagues in a 
dynamic retrospective framework with real-life vaccine 
mismatch.
Assuming 70% cross-protection of the efficacy of a 
matching vaccine, the model predicted that QIV would 
have prevented, on average, about 16% more B lineage 
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cases than TIV over the period 2000-2013 [30]. The el-
derly (≥ 65 years) and adults aged 50-64 years were seen 
to benefit most from QIV, with 21% and 18% reduc-
tions, respectively, in B lineage cases [30].
Van Bellinghen et al. conducted a lifetime economic 
evaluation of QIVs in comparison with TIVs in elderly 
people and clinical risk groups in the UK. Using a multi-
cohort Markov model, they estimated that quadrivalent 
influenza vaccination could further reduce the disease 
burden of influenza. The QIVs would be expected to re-
sult in substantial health benefits, reducing the number 
of symptomatic influenza cases, medical visits, compli-
cations, hospitalizations for complications and deaths, in 
comparison with TIVs [31]. In the UK, another study by 
Meier et al. applied a lifetime, multi-cohort static Mar-
kov model involving seven age-groups, and obtained 
analogous findings [32].
Thommes EW and colleagues used an age-stratified, dy-
namic four-strain transmission model which incorporated 
strain interaction, transmission-rate seasonality and age-
specific mixing in the population, in order to demonstrate 
the cost-effectiveness of quadrivalent influenza vaccines 
in Canada and the United Kingdom. The results of this 
analysis revealed that switching from trivalent to quadri-
valent vaccines would be a cost-effective means of further 
reducing the burden of influenza in both countries [33].
You JH and colleagues simulated the outcomes of 
QIV vs. TIV in 6 age-groups: 0-4 years, 5-9 years, 10-
14 years, 15-64 years, 65-79 years and ≥ 80 years. Direct 
cost alone, direct and indirect costs, and loss of quality-
adjusted life-years (QALYs) due to TIV-unmatched in-
fluenza B infection were simulated for each study arm. 
In the base-case analysis, QIV was more effective than 
TIV in all age-groups, and proved to be cost-effective 
from the societal perspective in all age-groups, except 
for those aged 15-64  years. From the healthcare pro-
vider’s perspective, QIV seemed to be cost-effective in 
very young (6 months – 9 years) and older (≥ 80 years) 
age-groups [34].
In Italy, a lifetime, multi-cohort, static Markov model 
was constructed, and was run in one-year cycles for a 
lifetime (Maximum age: 100 years). The analysis dem-
onstrated that QIV would be cost-effective compared 
with TIV. Specifically, QIV would be expected to reduce 
the number of influenza cases (by about 1,413.887), 
complications (by about 169,638), hospitalizations for 
complications (by about 41,862) and influenza deaths 
(by about 20,905). The incremental cost-effectiveness 
ratio (ICER) was € 18,883/QALY for the base case [8].
Conclusions
Influenza B viruses have a considerable public health 
burden, particularly among children and at-risk subjects. 
The belief that influenza B illness is less severe than 
influenza A leads to underestimation of its real impact. 
However, the type B influenza virus causes 20% to 25% 
of influenza infections worldwide. Since the mid-1980s, 
surveillance data have shown frequent co-circulation 
of both influenza  B lineages, B/Victoria-like and B/
Yamagata-like, during influenza seasons. The conven-
tional TIVs, containing only a single B strain, showed 
limited ability to induce effective protection when major 
or minor mismatches between the influenza B vaccine 
component and the circulating strains occurred, thus 
substantially reducing the clinical effectiveness of the 
trivalent influenza vaccine [35].
The availability of QIVs may contribute to overcoming 
the well-known difficulties of predicting the circulating 
B  lineage and choosing the right influenza B vaccine 
component in trivalent influenza vaccines (TIVs) [36].
In recent years, two QIVs, an inactivated vaccine and 
a live-attenuated vaccine, have been developed and li-
censed for human use on the basis of the good safety, 
tolerability and immunogenicity profiles demonstrated 
during the entire pre-marketing research process [37]. In 
some countries, such as Canada, national guidelines now 
recommend QIVs in preference to trivalent vaccines for 
use in children and young people [38].
Available models simulating the inclusion of QIVs in 
influenza immunization programs support the benefits 
of this new preventive tool in terms of reductions in 
symptomatic influenza cases and related complications. 
Indeed, QIVs could reduce both direct costs in term of 
medical visits, hospitalizations and antibiotic prescrip-
tions, and indirect costs related to working days lost by 
affected people and their caregivers.
However, some issues need to be addressed in the near 
future. In particular, estimations from simulation models 
should be confirmed by effectiveness studies in the field 
and more cost-effectiveness analyses should be conduct-
ed in order to verify the expected advantages in different 
epidemiological scenarios.
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